Analyst Scoreboard: 4 Ratings For VYNE Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have rated VYNE Therapeutics (NASDAQ:VYNE) with a consistent 'Buy' rating and a stable price target of $5.75. Despite a negative revenue trend and low net margins, the company shows strong ROE and ROA, and maintains a conservative debt management approach.
June 14, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have consistently rated VYNE Therapeutics with a 'Buy' rating and a stable price target of $5.75. Despite facing revenue challenges and low net margins, the company demonstrates strong ROE and ROA, and maintains a conservative debt management approach.
The consistent 'Buy' rating and stable price target of $5.75 from analysts indicate positive sentiment towards VYNE Therapeutics. The company's strong ROE and ROA, along with conservative debt management, are positive indicators despite the negative revenue trend and low net margins.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100